Showing results (21-30 of 297) with videos related to
Sort By:
Pageof 30
Journal of Primary Care & Community Health|January 22, 2016
Health Promotion Through Existing Community Structures: A Case of Churches' Roles in Promoting Rotavirus Vaccination in Rural ZambiaAustin Wesevich, Jenala Chipungu, Mercy Mwale, et al.Cancer Chemotherapy and Pharmacology|October 21, 2019
Alternative dosing regimens for atezolizumab: right dose, wrong frequencyDaniel A Goldstein, Mark J RatainClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2015
Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical TrialsManish R Sharma, Mark J RatainBritish Journal of Clinical Pharmacology|January 18, 2011
Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitorsYong Liu, Jacqueline Ramírez, Mark J RatainJCO Oncology Practice|February 4, 2026
TPMT-Cisplatin: Lessons in Citation Integrity and Scientific OversightYoungwoo Cho, Thomas Chen, Mark J RatainClinical Pharmacology and Therapeutics|December 2, 2017
Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase InhibitorsEtienne Chatelut, René Bruno, Mark J RatainFuture Oncology (London, England)|April 9, 2010
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapyJacqueline Ramírez, Mark J Ratain, Federico InnocentiBioinformatics and Biology Insights|April 9, 2008
The HapMap Resource is Providing New Insights into Ourselves and its Application to PharmacogenomicsWei Zhang, Mark J Ratain, M Eileen DolanOncogene|October 7, 2003
Pharmacogenomics: road to anticancer therapeutics nirvana?Apurva A Desai, Federico Innocenti, Mark J RatainJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Randomized discontinuation design: application to cytostatic antineoplastic agentsGary L Rosner, Walter Stadler, Mark J RatainPageof 30